Reuters logo
8 months ago
BRIEF-Orexigen Therapeutics announces distributorship agreement with Consilient Health for Mysimba
December 8, 2016 / 12:44 PM / 8 months ago

BRIEF-Orexigen Therapeutics announces distributorship agreement with Consilient Health for Mysimba

Dec 8 (Reuters) - Orexigen Therapeutics Inc -

* Expects Mysimba to be available in UK and Ireland in Q2 of 2017

* Consilient will be responsible for all commercialization activity and expenses

* Will supply Mysimba tablets to consilient for a transfer price and potential regulatory and commercial milestone payments

* Orexigen Therapeutics announces commercialization and distributorship agreement with Consilient Health Ltd. for Mysimba (Naltrexone HCL / Bupropion HCL prolonged release) in the uk and ireland Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below